Wall Street Zen Upgrades Sensus Healthcare (NASDAQ:SRTS) to Hold

Wall Street Zen upgraded shares of Sensus Healthcare (NASDAQ:SRTS - Free Report) from a sell rating to a hold rating in a report released on Saturday.

Other equities research analysts have also issued reports about the stock. Lake Street Capital decreased their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Maxim Group decreased their target price on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Sensus Healthcare in a research note on Friday, April 4th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $11.67.

Sensus Healthcare Stock Performance

SRTS stock remained flat at $4.82 during midday trading on Friday. The company had a trading volume of 62,515 shares, compared to its average volume of 194,819. The stock has a market capitalization of $79.24 million, a P/E ratio of 48.20 and a beta of 1.32. Sensus Healthcare has a fifty-two week low of $4.01 and a fifty-two week high of $9.33. The business has a 50 day simple moving average of $4.67 and a 200-day simple moving average of $5.69.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.20). The business had revenue of $8.34 million during the quarter, compared to the consensus estimate of $7.23 million. Sensus Healthcare had a net margin of 4.56% and a return on equity of 3.34%. On average, equities analysts predict that Sensus Healthcare will post 0.32 earnings per share for the current year.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. purchased a new stake in shares of Sensus Healthcare in the 4th quarter worth $27,000. Barclays PLC purchased a new stake in shares of Sensus Healthcare in the 4th quarter worth $35,000. Larson Financial Group LLC purchased a new stake in shares of Sensus Healthcare in the 1st quarter worth $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Sensus Healthcare in the 4th quarter worth $47,000. Finally, IFP Advisors Inc purchased a new stake in shares of Sensus Healthcare in the 4th quarter worth $95,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.